Pneumococcal Vaccines – How Many Serotypes are Enough?
Streptococcus pneumoniae causes meningitis, pneumonia, septicemia, arthritis, sinusitis and otitis media specially in children and over 65 y age groups. It contributes significantly to under-five mortality and morbidity worldwide as well as in India. Use of pneumococcal vaccine seems to be the most effective measure to decrease the disease burden and reduction of under-five mortality. Many countries have already included Pneumococcal Conjugate Vaccines (PCV) in their National Immunization Programmes (NIP). Government of India has announced recently to include PCV13 in NIP in a phased manner. Superiority of a vaccine over the other depends upon serotype coverage, vaccine efficacy, cost effectiveness and safety profile. These facts will be discussed for the vaccines available in India. Further research is warranted to know the disease burden and develop vaccines to have more serotype coverage.
KeywordsInvasive pneumococcal disease (IPD) Pneumococcal conjugate vaccine (PCV) National immunization programme (NIP)
Compliance with Ethical Standards
Conflict of Interest
Source of Funding
- 1.UNICEF/WHO. Pneumonia: The forgotten killer of children. Geneva: WHO; s Available at: www.who.int/child_adolescent_health/documents/9280640489/en/. Accessed 3 May 2017.S
- 3.Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49:1–35.Google Scholar
- 4.Immunization, vaccine and biological. Pneumococcal disease World Health Organization (WHO). Available at: www.who.int/immunization/topics/pneumococcal_disease/en/. Accessed 9 May 2017.
- 6.Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000–2012. MMWR Morb Mortal Wkly Rep. 2013;62:308–11.Google Scholar
- 11.Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian network for surveillance of resistant pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56:1418–26.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Lancet. 1999;353:1216-21Google Scholar
- 13.Paediatric on call. Child Health Care. Conjugate pneumococcal vaccine 2011. Available at: http://www.pediatriconcall.com/fordoctor/diseasesandcondition/immunization_vaccination/pneumococcal_vaccine.asp. Accessed 7 May 2017.
- 14.Indian Academy of Pediatrics Committee on Immunization (IAPCOI). Consensus recommendations on immunization, 2008. Indian Pediatr. 2008;45:635–648.Google Scholar
- 15.Indian Academy of Pediatrics Committee on Immunization (IAPCOI). Consensus recommendations on immunization and IAP immunization timetable 2012. Indian Pediatr. 2012;49:549-64.Google Scholar
- 23.Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic non-inferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–203.CrossRefPubMedGoogle Scholar
- 25.Lalwani S, Chatterjee S, Chhatwal J, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenza protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study. Hum Vaccin Immunother. 2012;8:612–22.CrossRefPubMedGoogle Scholar
- 26.Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;4:CD004977.Google Scholar
- 29.Madhi SA, Klugman KP. The Vaccine Trialist Group. A role of Streptococcus Pneumoniae in virus-associated pneumonia. Nat Med. 2004;10:811-3.Google Scholar
- 33.Roca A, Hill PC, Townend J, et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoSMed. 2011;8:e1001107.Google Scholar
- 38.Pneumococcal vaccine. WHO position paper. 2012. Available at: http://www.who.int/immunization/documents/positionpapers/en/. Accessed 5 May 2017.
- 40.Bravo LC; Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group. Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine. 2009;27:7282-91.Google Scholar
- 41.Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54:893–7.Google Scholar
- 43.Katoh S, Suzuki M, Ariyoshi K, Morimoto K. Serotype replacement in adult pneumococcal pneumonia after the introduction of seven-valent pneumococcal conjugate vaccines for children in Japan: a systematic literature review and pooled data analysis. Jpn J Infect Dis. 2017; doi: 10.7883/yoken.JJID.2016.311.